TürkiyeResearch and clinical trials
Simple test tried to measure heart and diabetes risk in 14 children with Bardet-Biedl syndrome in Istanbul
A study published in a journal and reviewed by independent scientists. Even so, a single study is not conclusive; it needs to be replicated.
At Istanbul Faculty of Medicine, 14 children were studied. Researchers tried a measure called SPISE, calculated from weight and blood fats. This measure was linked to the burden of metabolic syndrome. It performed well in identifying metabolic syndrome in adolescents. Because the number of patients was small, the results are not definitive.
What does it mean for patients and families?
Where insulin testing is not available, this simple calculation may help with monitoring. It needs to be confirmed in larger studies.
Source
Scientific paper: Assessment of cardiometabolic risk using single point insulin sensitivity estimator (SPISE) in pediatric Bardet-Biedl Syndrome: a pilot study. Orphanet Journal of Rare Diseases, 2026. DOI: 10.1186/s13023-026-04353-y · PubMed 42557588
The source page was opened and read on October 7, 2026. Summary prepared by the Doktorclub editorial team and translated from Turkish; it has not yet been reviewed by a physician (a scientific board is being set up).
This page is translated from the Turkish original.
Related disease: Bardet-Biedl syndrome (BBS)
This page reports a development; it is not a treatment recommendation. Your doctor decides whether a treatment is right for you.